Abstract
Although patients can present with non-specific symptoms and minimal clinical signs, generally, in the community, patients with heart failure present with symptoms of dyspnoea or fluid retention. In order to confirm (or refute) the diagnosis, NICE recommends natriuretic peptide testing (ideally N-terminal pro B-type natriuretic peptide; NT-proBNP) in all patients with suspected heart failure. An NT-proBNP level > 2,000 ng/L is highly suggestive of heart failure and NICE recommends echocardiography and specialist review within 2 weeks. Conversely, an NT-proBNP level < 400 ng/L suggests that a diagnosis of heart failure is unlikely. Patients with an NT-proBNP of 400-2,000 ng/L should have echocardiography and specialist assessment within 6 weeks.
| Original language | English |
|---|---|
| Pages (from-to) | 21-25 |
| Number of pages | 5 |
| Journal | The Practitioner |
| Volume | 263 |
| Issue number | 1823 |
| Publication status | Published - 22 Feb 2020 |
Fingerprint Dive into the research topics of 'Optimising outcomes in chronic heart failure'. Together they form a unique fingerprint.
Cite this
Mordi, I. R., & Szwejkowski, B. R. (2020). Optimising outcomes in chronic heart failure. The Practitioner, 263(1823), 21-25. https://www.thepractitioner.co.uk/Special-Report/11068-/Optimising-outcomes-in-chronic-heart-failure